S4 (Andarine) - 25mgs/capsule - 60 capsules/pack
Due to the difficulty of researching with liquids, dosing/crystalization and user feedback. We have decided to switch to capsule based SARMS.
S4 (Andarine) is an investigational selective androgen receptor modulator (SARM) developed by GTX.INC for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, us the non-steroidal androgen antagonist bicalutamide as a lead compound.
Andarine is an orally active partial agonist for androgen receptors. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.This suggests that it is able to competitively block binding of dihydrostestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.
S-4 (3 mg/kg/day) was also able to restore skeletal muscle (i.e., soleus muscle) and strength in castrated rats, important and applicable for the treatment of muscle wasting and male HRT.
A 120-day study comparing SARM S-4 and dihydrotestosterone (DHT) treatment in ovariectomized rats demonstrated that S-4 was able to maintain bone mass and bone strength to the levels of intact controls and exhibited greater efficacy than DHT.
Testosterone shows a very similar increase in muscle and prostate growth in a dose dependent manner where S-4 shows a great increase in muscle growth with prostate growth staying largely uniform.
S-4 also demonstrated the ability to improve skeletal muscle strength, increase lean body mass (LBM), reduce body fat, and prevent bone loss.
This article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.